Aliases & Classifications for Hypoxia

MalaCards integrated aliases for Hypoxia:

Name: Hypoxia 53 17 71

Classifications:



External Ids:

UMLS 71 C0242184

Summaries for Hypoxia

Novus Biologicals : 55 Hypoxia is a pathological condition in which the body as a whole (generalized hypoxia) or region of the body (tissue hypoxia) is deprived of adequate oxygen supply. Hypoxia contributes significantly to the pathophysiology of major categories of human disease, including myocardial and cerebral ischemia, cancer, pulmonary hypertension, congenital heart disease and chronic obstructive pulmonary disease. Hypoxia inducible factor-1 (HIF-1) is a transcription factor that regulates adaptive responses to a lack of oxygen in mammalian cells. HIF-1 consists of two proteins, HIF-1 alpha and HIF-1 beta. HIF-1 alpha accumulates under hypoxic conditions whereas HIF-1 beta is constitutively expressed. HIF-1 alpha is an important mediator of the hypoxic response of tumor cells and controls the up-regulation of a number of factors important for solid tumor expansion including the angiogenic factor VEGF.

MalaCards based summary : Hypoxia is related to chronic mountain sickness and acute mountain sickness, and has symptoms including seizures, fever and dyspnea. An important gene associated with Hypoxia is KMT2A (Lysine Methyltransferase 2A), and among its related pathways/superpathways are CDK-mediated phosphorylation and removal of Cdc6 and Pathways in cancer. The drugs Bosentan and Fentanyl have been mentioned in the context of this disorder. Affiliated tissues include endothelial, smooth muscle and prostate, and related phenotypes are Decreased viability and Decreased viability

NINDS : 53 Cerebral hypoxia refers to a condition in which there is a decrease of oxygen supply to the brain even though there is adequate blood flow. Drowning, strangling, choking, suffocation, cardiac arrest, head trauma, carbon monoxide poisoning, and complications of general anesthesia can create conditions that can lead to cerebral hypoxia. Symptoms of mild cerebral hypoxia include inattentiveness, poor judgment, memory loss, and a decrease in motor coordination. Brain cells are extremely sensitive to oxygen deprivation and can begin to die within five minutes after oxygen supply has been cut off. When hypoxia lasts for longer periods of time, it can cause coma, seizures, and even brain death.  In brain death, there is no measurable activity in the brain, although cardiovascular function is preserved. Life support is required for respiration.

Wikipedia : 74 Hypoxia is a condition in which the body or a region of the body is deprived of adequate oxygen supply... more...

Related Diseases for Hypoxia

Diseases related to Hypoxia via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 1459)
# Related Disease Score Top Affiliating Genes
1 chronic mountain sickness 31.9 VEGFA EPAS1 EGLN3
2 acute mountain sickness 31.4 VHL VEGFA HIF1AN HIF1A EGLN1
3 renal cell carcinoma, nonpapillary 31.4 VHL VEGFA MTOR HIF1AN HIF1A EPAS1
4 polycythemia 31.1 VHL HIF1A EPAS1 EGLN3 EGLN2 EGLN1
5 pheochromocytoma 30.8 VHL VEGFA HIF1A EPAS1 EGLN3 EGLN2
6 kidney cancer 30.8 VHL VEGFA MTOR HIF1A EPAS1 CA9
7 soft tissue sarcoma 30.7 VEGFA HIF1A
8 paraganglioma 30.6 VHL HIF1A EPAS1 EGLN1
9 von hippel-lindau syndrome 30.6 VHL VEGFA HIF1A EPAS1 EGLN1
10 hemangioma 30.5 VHL VEGFA MTOR HIF1A
11 ductal carcinoma in situ 30.5 VEGFA HIF1A CA9
12 clear cell renal cell carcinoma 30.5 VHL VEGFA MTOR HIF1A EPAS1 EP300
13 hemangioblastoma 30.4 VHL VEGFA HIF1A EPAS1
14 ovarian clear cell carcinoma 30.4 VEGFA MTOR HIF1A
15 estrogen-receptor positive breast cancer 30.3 VEGFA MTOR HIF1A
16 ovarian clear cell adenocarcinoma 30.1 VEGFA MTOR HIF1A
17 fumarate hydratase deficiency 30.0 VHL HIF1A
18 pheochromocytoma-paraganglioma 30.0 VHL EGLN2 EGLN1
19 renal cell carcinoma, papillary, 1 30.0 VHL VEGFA MTOR HIF1A CA9
20 primary polycythemia 29.9 VHL HIF1A EPAS1 EGLN3 EGLN2 EGLN1
21 gastrointestinal stromal tumor 29.9 VEGFA HIF1A EPAS1 EP300
22 erythrocytosis, familial, 2 29.9 VHL HIF1AN HIF1A EPAS1 EGLN3 EGLN2
23 acquired polycythemia 29.8 EPAS1 EGLN1
24 clear cell papillary renal cell carcinoma 29.8 VHL CA9
25 retinal hemangioblastoma 29.7 VHL VEGFA HIF1A EPAS1
26 neuroendocrine tumor 29.7 VEGFA MTOR EPAS1
27 hematologic cancer 29.0 VEGFA MTOR KMT2A EP300
28 cerebral hypoxia 11.6
29 anoxia 11.4
30 neonatal hypoxic and ischemic brain injury 11.3
31 pulmonary hypertension owing to lung disease and/or hypoxia 11.2
32 asphyxia neonatorum 11.1
33 exudative vitreoretinopathy 1 11.1
34 polycythemia due to hypoxia 11.1
35 pulmonary hypertension 11.0
36 pulmonary edema 11.0
37 sleep apnea 11.0
38 methemoglobinemia due to deficiency of methemoglobin reductase 11.0
39 respiratory underresponsiveness to hypoxia and hypercapnia 10.9
40 ischemia 10.9
41 apnea of prematurity 10.9
42 severe acute respiratory syndrome 10.9
43 hantavirus pulmonary syndrome 10.9
44 congenital extrahepatic portosystemic shunt 10.9
45 tempi syndrome 10.9
46 pneumothorax, primary spontaneous 10.8
47 methemoglobinemia and ambiguous genitalia 10.8
48 exudative vitreoretinopathy 2, x-linked 10.8
49 exudative vitreoretinopathy 4 10.8
50 tricuspid atresia 10.8

Graphical network of the top 20 diseases related to Hypoxia:



Diseases related to Hypoxia

Symptoms & Phenotypes for Hypoxia

UMLS symptoms related to Hypoxia:


seizures, fever, dyspnea, vertigo, hemoptysis, cachexia, apnea, headache, syncope, cyanosis, edema, chills, icterus, signs and symptoms, signs and symptoms, digestive, hot flushes, cheyne-stokes respiration, coughing, hoarseness, increased sweating, anoxemia, signs and symptoms, respiratory, sneezing, hyperoxia, motor symptom, skin symptoms, physical symptom, physical appearance, body

GenomeRNAi Phenotypes related to Hypoxia according to GeneCards Suite gene sharing:

26 (show all 13)
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Decreased viability GR00055-A-1 9.8 MTOR
2 Decreased viability GR00055-A-2 9.8 MTOR
3 Decreased viability GR00221-A-1 9.8 MTOR VHL
4 Decreased viability GR00221-A-2 9.8 EGLN3 EP300 VHL
5 Decreased viability GR00221-A-4 9.8 MTOR
6 Decreased viability GR00240-S-1 9.8 PSMA7
7 Decreased viability GR00249-S 9.8 ARNT CITED2 EGLN3 PSMA7 VEGFA VHL
8 Decreased viability GR00301-A 9.8 EGLN3 VHL
9 Decreased viability GR00342-S-1 9.8 MTOR
10 Decreased viability GR00342-S-2 9.8 MTOR
11 Decreased viability GR00381-A-1 9.8 EGLN2 EGLN3 HIF1AN PSMA7
12 Decreased viability GR00386-A-1 9.8 ARNT TIGAR
13 Decreased viability GR00402-S-2 9.8 EGLN1 EGLN3 HIF3A KMT2A PSMA7

MGI Mouse Phenotypes related to Hypoxia:

46 (show all 20)
# Description MGI Source Accession Score Top Affiliating Genes
1 cardiovascular system MP:0005385 10.47 ARNT CITED2 EGLN1 EGLN2 EGLN3 EP300
2 homeostasis/metabolism MP:0005376 10.41 ARNT CITED2 EGLN1 EGLN2 EGLN3 EP300
3 cellular MP:0005384 10.4 ARNT EGLN1 EGLN2 EGLN3 EP300 HIF1A
4 hematopoietic system MP:0005397 10.4 ARNT CA9 CITED2 EGLN1 EGLN2 EGLN3
5 immune system MP:0005387 10.37 ARNT CA9 CITED2 EGLN1 EGLN2 EGLN3
6 growth/size/body region MP:0005378 10.35 ARNT CITED2 EGLN1 EGLN2 EGLN3 EP300
7 embryo MP:0005380 10.34 ARNT CITED2 EGLN1 EGLN2 EGLN3 EP300
8 mortality/aging MP:0010768 10.28 ARNT CA9 CITED2 EGLN1 EGLN3 EP300
9 craniofacial MP:0005382 10.27 ARNT CITED2 EGLN1 EGLN2 EGLN3 EP300
10 endocrine/exocrine gland MP:0005379 10.2 ARNT CA9 CITED2 EGLN3 EP300 HIF1A
11 muscle MP:0005369 10.18 EGLN1 EGLN2 EGLN3 EP300 EPAS1 HIF1A
12 integument MP:0010771 10.13 ARNT EGLN1 EGLN2 EGLN3 HIF1A HIF1AN
13 liver/biliary system MP:0005370 10.13 ARNT EGLN1 EGLN2 EGLN3 EPAS1 HIF1A
14 digestive/alimentary MP:0005381 10.11 CA9 CITED2 EP300 HIF1A TIGAR VEGFA
15 limbs/digits/tail MP:0005371 10 CITED2 EGLN2 EGLN3 HIF1A KMT2A VEGFA
16 nervous system MP:0003631 10 ARNT CITED2 EGLN1 EGLN3 EP300 EPAS1
17 neoplasm MP:0002006 9.87 ARNT EP300 HIF1A KMT2A TIGAR VEGFA
18 normal MP:0002873 9.85 ARNT CITED2 EGLN3 EP300 HIF1A HIF1AN
19 renal/urinary system MP:0005367 9.65 ARNT CITED2 EGLN1 EP300 HIF1A KMT2A
20 respiratory system MP:0005388 9.28 CITED2 EGLN1 EP300 EPAS1 HIF1A HIF1AN

Drugs & Therapeutics for Hypoxia

Drugs for Hypoxia (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 414)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Bosentan Approved, Investigational Phase 4 147536-97-8 104865
2
Fentanyl Approved, Illicit, Investigational, Vet_approved Phase 4 437-38-7 3345
3
Terbutaline Approved Phase 4 23031-25-6 5403
4
Ipratropium Approved, Experimental Phase 4 22254-24-6, 60205-81-4 43232 657309
5
Fluticasone Approved, Experimental Phase 4 90566-53-3 62924
6
Atropine Approved, Vet_approved Phase 4 5908-99-6, 51-55-8 174174
7
Succinylcholine Approved Phase 4 306-40-1 5314
8
Nebivolol Approved, Investigational Phase 4 152520-56-4, 118457-14-0, 99200-09-6 71301
9
Carvedilol Approved, Investigational Phase 4 72956-09-3 2585
10
Bisoprolol Approved Phase 4 66722-44-9 2405
11
Methazolamide Approved Phase 4 554-57-4 4100 5353756
12
Cetirizine Approved Phase 4 83881-51-0 2678
13
Histamine Approved, Investigational Phase 4 51-45-6, 75614-87-8 774
14
Alprostadil Approved, Investigational Phase 4 745-65-3 149351 5280723
15
Pioglitazone Approved, Investigational Phase 4 111025-46-8 4829
16
Losartan Approved Phase 4 114798-26-4 3961
17
Doxapram Approved, Vet_approved Phase 4 309-29-5 3156
18
Ketamine Approved, Vet_approved Phase 4 6740-88-1 3821
19
Alfentanil Approved, Illicit Phase 4 71195-58-9 51263
20
Dexmedetomidine Approved, Vet_approved Phase 4 113775-47-6 68602 5311068
21
Trazodone Approved, Investigational Phase 4 19794-93-5 5533
22
Sevoflurane Approved, Vet_approved Phase 4 28523-86-6 5206
23
Rocuronium Approved Phase 4 119302-91-9, 143558-00-3 441290
24
Acetazolamide Approved, Vet_approved Phase 4 59-66-5 1986
25
Amlodipine Approved Phase 4 88150-42-9 2162
26
Angiotensin II Approved, Investigational Phase 4 68521-88-0, 4474-91-3, 11128-99-7 172198
27
Valsartan Approved, Investigational Phase 4 137862-53-4 60846
28
Acetylcysteine Approved, Investigational Phase 4 616-91-1 12035
29
Creatine Approved, Investigational, Nutraceutical Phase 4 57-00-1 586
30
Cysteine Approved, Nutraceutical Phase 4 52-90-4 5862
31
Maleic acid Experimental Phase 4 110-16-7 444266
32 Endothelin Receptor Antagonists Phase 4
33 Insulin, Globin Zinc Phase 4
34 insulin Phase 4
35 Albuterol Phase 4
36 Mydriatics Phase 4
37 Ether Phase 4
38 Liver Extracts Phase 4
39 Hydroxymethylglutaryl-CoA Reductase Inhibitors Phase 4
40
Salmeterol xinafoate Phase 4 94749-08-3 56801
41 Cholinergic Antagonists Phase 4
42
Beclomethasone Phase 4 4419-39-0 20469
43 Tiotropium Bromide Phase 4 136310-93-5
44 Parasympatholytics Phase 4
45 Muscarinic Antagonists Phase 4
46 Cholinergic Agents Phase 4
47 Central Nervous System Stimulants Phase 4
48 Anti-Arrhythmia Agents Phase 4
49 Excitatory Amino Acid Antagonists Phase 4
50 Adrenergic alpha-1 Receptor Antagonists Phase 4

Interventional clinical trials:

(show top 50) (show all 969)
# Name Status NCT ID Phase Drugs
1 Sevoflurane-based Volatile Induction and Maintenance of Anaesthesia (VIMA) Strategy Decreases the Risk of Postoperative Delirium in Elderly Patients With Registered Cerebral Hypoxemia Episodes During General Surgery Unknown status NCT02133638 Phase 4 Sevoflurane;Propofol
2 Comparison of Efficacy Different Treatment Regimens in Pulmonary Hypertension Secondary to Lung Disease and or Hypoxia Unknown status NCT01449253 Phase 4 Sildenafil;Bosentan
3 Long-Term Oxygen Therapy (LTOT) in Chronic Obstructive Pulmonary Disease (COPD) Patients With Moderate Chronic Hypoxemia and Chronic Heart Failure (CHF) Unknown status NCT00668408 Phase 4
4 Continuous Positive Airway Pressure for Treatment of Postoperative Hypoxemia in Liver Transplant Unknown status NCT00510770 Phase 4
5 Atropine Versus no Atropine for Neonatal Rapid Sequence Intubation Unknown status NCT01595399 Phase 4 atropine;Placebo
6 Hypoventilation and High Altitude Chronic Polycythemia: Acetazolamide as a Possible Treatment Completed NCT00424970 Phase 4 acetazolamide
7 Nasal Budesonide in Children With Rhinitis and/or Mild Obstructive Sleep Apnea Syndrome Completed NCT00560586 Phase 4 Budesonide;placebo
8 Nebivolol Versus Bisoprolol Versus Carvedilol in Heart Failure: Effects on Exercise Capacity and Hypoxia, Chemoreceptor Response, Pulmonary Function Completed NCT00517725 Phase 4 carvedilol;bisoprolol;Nebivolol
9 Effect of Systemic Hypoxia and Hyperoxia on Retinal Oxygen Saturation Completed NCT01692821 Phase 4 100% oxygen breathing;15% oxygen in N2 breathing;12% oxygen in N2 breathing
10 Comparison of the Cardiovascular, Metabolic and Respiratory Effects of Nebivolol and Carvedilol at High Altitude in Healthy Subjects. Completed NCT00924833 Phase 4 placebo;Carvedilol;Nebivolol
11 Continuous Positive Airway Pressure (CPAP) and Acetazolamide for Treatment of Patients With the Obstructive Sleep Apnea Syndrome at Altitude Completed NCT00928655 Phase 4 acetazolamide;placebo
12 Hyperoxia: An Unrecognized Mechanism for Inducing "Hypoxia-Like" Symptoms Completed NCT03268590 Phase 4 Oxygen
13 Bispectral Index and Clinical Parameters Evaluation in Different Dental Procedures With Nitrous Oxide and Oxygen Sedation Completed NCT02671578 Phase 4 Nitrous Oxide
14 The Effect of Carbonic Anhydrase Inhibitors on the Pulmonary System Response to Muscle Fatigue. Completed NCT02758470 Phase 4 Acetazolamide;Methazolamide
15 Acute Ventilatory Response to Hypoxia During Sedation With Dexmedetomidine Compared to Propofol in Healthy Male Volunteers Completed NCT01873612 Phase 4
16 Effect of an H1 Receptor Antagonist on Exercise Performance in Hypoxia Completed NCT03192488 Phase 4 Cetirizine;Placebo oral capsule
17 The Effect of Carbonic Anhydrase Inhibitors on the Pulmonary System Response to Hypoxia Completed NCT02760121 Phase 4 Acetazolamide;Methazolamide;Placebo
18 Lipo-prostaglandin E1 Improves Renal Hypoxia Evaluated by BOLD-MRI in Patients Completed NCT02628106 Phase 4 Lipo-PGE1
19 Can Muscle Dysfunction in COPD be Altered by Oxygenation in Patients With Intermittent Hypoxia on Exertion? Completed NCT01722370 Phase 4 Oxygen;Medical air equivalent
20 5-hydroxytryptophan and Creatine for Treatment Resistant Depression Associated With Hypoxia in Females Completed NCT02356107 Phase 4 5-hydroxytryptophan and Creatine monohydrate
21 GlitazOne Treatment for Coronavirus HypoxiA, a Safety and Tolerability Open Label With Matching Cohort Pilot Study Completed NCT04473274 Phase 4 Pioglitazone
22 Effect of Angiotensin Receptor Blockers on Periodic Breathing During Sleep in Hypoxia Completed NCT03335904 Phase 4 Losartan;Placebo
23 Acute Effect of Indacaterol Maleate on Static and Dynamic Lung Volume in COPD Subjects. Completed NCT01377051 Phase 4 Indacaterol maleate;Placebo
24 Doxapram as an Additive to Propofol Sedation in Sedation for Endoscopic Retrograde Cholangiopancreatography Completed NCT02171910 Phase 4 Doxapram;Placebo
25 Ketamine Effect on Recovery and Respiratory Outcomes After Laparoscopic Gastric Reduction: A Randomized, Double-Blinded, Placebo Controlled Study Completed NCT01997515 Phase 4 Ketamine;placebo
26 Recruitment Maneuver Increases Oxygenation After Intubation in Hypoxemic ICU Patients: a Randomized Controlled Study Completed NCT01014299 Phase 4
27 The Effect of Nasal Cannula During the First 2 Hours Postoperative in Patient Undergoing Thoracotomy Completed NCT01725464 Phase 4
28 Early Nasal High Flow Oxygen Therapy for Prevention of Postoperative Hypoxemia After Abdominal Surgery: A Multicenter Randomized Controlled Trial Completed NCT01887015 Phase 4
29 The Optimal Regimen of Alfentanil in Propofol Sedative Fibro-bronchoscopy:a Prospective Randomized, Double-blind, Placebo-controlled Trial Completed NCT01470170 Phase 4 Alfentanil;Normal saline;Propofol
30 Preoxygenation Using Noninvasive Ventilation Prior Intubation in Hypoxemic Patients Completed NCT00472160 Phase 4
31 Acute Effects of Sodium-glucose Cotransporter-2 Inhibition on Renal Oxygenation and Autonomic Function in Type 1 Diabetes Completed NCT04193566 Phase 4 Forxiga
32 Reducing the Need for Intensive Care Unit in Hospitalized Patients With Early Respiratory Failure Using the Non-invasive Ventilation Technique. A Multicentre Randomized Study. Recruiting NCT01572337 Phase 4
33 The Effects of Hyperoxia on Organ Dysfunction and Outcome in Critically Ill Patients With SIRS Recruiting NCT02321072 Phase 4 Oxygen
34 Treatment of Sleep Apnea in Patients With Cervical Spinal Cord Injury Recruiting NCT02922894 Phase 4 Trazodone;Placebo
35 REgistry-based Randomized Controlled Trial of Treatment Duration and Mortality in Long-term OXygen Therapy (REDOX) A Multicenter, Phase IV, Registry-Based, Randomized Controlled Trial (R-RCT) Recruiting NCT03441204 Phase 4 LTOT 24 h/day;LTOT 15h/day
36 A Randomized, Double-blind, Placebo-controlled Trial of 5-hydroxytryptophan and Creatine for SSRI or SNRI Augmentation in Treatment Resistant Depression Associated With Hypobaric Hypoxia in Females Recruiting NCT02922725 Phase 4 5-hydroxytryptophan and Creatine
37 Impact of High-flow Nasal Cannula Oxygen (HFNC) Versus Noninvasive Ventilation Associated With Sleep Quality on Atrial Fibrillation in Hypoxemic Patients After Coronary Surgery Recruiting NCT02713737 Phase 4
38 Addition of Neuromuscular-Blocking Agents During Sevoflurane Induction in Infants : Potential Interest in Reducing Hypoxemia Episodes Recruiting NCT02589691 Phase 4 Rocuronium
39 Effect of Dexmedetomidine on Brain Homeostasis and Neurocognitive Outcome of Patients Undergoing Brain Tumor Exclusion Recruiting NCT04266665 Phase 4 Dexmedetomidine
40 Effect of Acetazolamide on Maximal Exercise Performance in Lowlanders Older Than 40 Years at Altitude: A Randomized, Placebo-controlled, Double-blind Parallel Trial Active, not recruiting NCT03536455 Phase 4 ACETAZOLAMIDE oral capsule;Placebo oral capsule
41 Effect of Acetazolamide on Lung Water Content by Ultrasound in Lowlanders Older Than 40 Years at Altitude: A Randomized, Placebo-controlled, Double-blind Parallel Trial Active, not recruiting NCT03539367 Phase 4 ACETAZOLAMIDE oral capsule;Placebo oral capsule
42 Effect of Acetazolamide on Visuo-motor Learning in Lowlanders Older Than 40 Years at Altitude: A Randomized, Placebo-controlled, Double-blind Parallel Trial Active, not recruiting NCT03536520 Phase 4 ACETAZOLAMIDE oral capsule;Placebo oral capsule
43 Effect of Acetazolamide on Sleep Disordered Breathing in Lowlanders Older Than 40 Years at Altitude: A Randomized, Placebo-controlled, Double-blind Parallel Trial Active, not recruiting NCT03536507 Phase 4 ACETAZOLAMIDE oral capsule;Placebo oral capsule
44 Effect of Acetazolamide on Right Heart Function During Exercise in Lowlanders Older Than 40 Years at Altitude: A Randomized, Placebo-controlled, Double-blind Parallel Trial Active, not recruiting NCT03537924 Phase 4 ACETAZOLAMIDE oral capsule;Placebo oral capsule
45 Effect of Acetazolamide on Right Heart Function at Rest in Lowlanders Older Than 40 Years at Altitude.: A Randomized, Placebo-controlled, Double-blind Parallel Trial Active, not recruiting NCT03540914 Phase 4 ACETAZOLAMIDE oral capsule;Placebo oral capsule
46 Effect of Acetazolamide on Postural Control in Lowlanders Older Than 40 Years at Altitude: A Randomized, Placebo-controlled, Double-blind Parallel Trial Active, not recruiting NCT03536429 Phase 4 ACETAZOLAMIDE oral capsule;Placebo oral capsule
47 Phase 4, Randomized, Placebo-controlled, Cross-over Trial to Assess the Effect of 4-week Ertugliflozin (SGLT-2 Inhibitor) Therapy on Renal Oxygenation by BOLD-MRI and Renal Oxygen Consumption by PET Using ¹¹C-acetate in T2DM Without Kidney Disease and Healthy Controls. Not yet recruiting NCT04027530 Phase 4 Ertugliflozin 15 mg
48 Cardiovascular and Metabolic Physiological Adaptations to Intermittent Hypoxia. Physiological Aspects and Expression of Receptors and Cellular Mediators Terminated NCT02058823 Phase 4 Placebo;Placebo;Valsartan;Amlodipine
49 Non-Invasive Ventilation in Early Severe Posttraumatic Hypoxia: a Randomized Controlled Trial Terminated NCT00557752 Phase 4
50 Modulation of Oxygen Sensor Reactivity to Mimic Altitude Acclimatization Terminated NCT01241513 Phase 4 NAC;Placebo

Search NIH Clinical Center for Hypoxia

Genetic Tests for Hypoxia

Anatomical Context for Hypoxia

MalaCards organs/tissues related to Hypoxia:

40
Endothelial, Smooth Muscle, Prostate, Breast, Brain, Bone Marrow, Cortex

Publications for Hypoxia

Articles related to Hypoxia:

(show top 50) (show all 30000)
# Title Authors PMID Year
1
Increased expression of hypoxia-induced factor 1α mRNA and its related genes in myeloid blood cells from critically ill COVID-19 patients. 61
33345622 2021
2
Role of dehydroepiandrosterone sulfate as a scavenging antioxidant: the evidence from Caenorhabditis elegans' nervous system under hypoxia. 61
33433471 2021
3
Hypoxia response element-directed expression of bFGF in dental pulp stem cells improve the hypoxic environment by targeting pericytes in SCI rats. 61
33553827 2021
4
TP53-induced glycolysis and apoptosis regulator alleviates hypoxia/ischemia-induced microglial pyroptosis and ischemic brain damage. 61
33269748 2021
5
The individual and combined effects of hypoxia and high-fat diet feeding on nutrient composition and flesh quality in Nile tilapia (Oreochromis niloticus). 61
33143967 2021
6
Acute and chronic effects of intravitreal bevacizumab on lung biomarkers of angiogenesis in the rat exposed to neonatal intermittent hypoxia. 61
33377400 2021
7
Involvement of TRPM2 Channel on Hypoxia-Induced Oxidative Injury, Inflammation, and Cell Death in Retinal Pigment Epithelial Cells: Modulator Action of Selenium Nanoparticles. 61
33389617 2021
8
Tibetan medicine Duoxuekang ameliorates hypobaric hypoxia-induced brain injury in mice by restoration of cerebrovascular function. 61
33246120 2021
9
Functional foods from the tropics to relieve chronic normobaric hypoxia. 61
33333240 2021
10
Quantitative In Vivo Monitoring of Hypoxia and Vascularization of Patient-Derived Murine Xenografts of Mantle Cell Lymphoma Using Photoacoustic and Ultrasound Imaging. 61
33455807 2021
11
Astragaloside IV improves angiogenesis under hypoxic conditions by enhancing hypoxia‑inducible factor‑1α SUMOylation. 61
33537820 2021
12
Isolated Plin5-deficient cardiomyocytes store less lipid droplets than normal, but without increased sensitivity to hypoxia. 61
33373698 2021
13
Metabolic adaptation in hypoxia and cancer. 61
33444690 2021
14
Memantine ameliorates cognitive impairment induced by exposure to chronic hypoxia environment at high altitude by inhibiting excitotoxicity. 61
33422543 2021
15
Trimetazidine alleviates hypoxia/reoxygenation-induced apoptosis in neonatal mice cardiomyocytes via up-regulating HMGB1 expression to promote autophagy. 61
32757698 2021
16
Ameliorative Effect of Ananas comosus on Cobalt Chloride-Induced Hypoxia in Caco2 cells via HIF-1α, GLUT 1, VEGF, ANG and FGF. 61
32654099 2021
17
Hypoxia-mediated drug resistance in breast cancers. 61
33278499 2021
18
Double whammy: Nitrate pollution heightens susceptibility to both hypoxia and heat in a freshwater salmonid. 61
33077222 2021
19
Significant difference between sirolimus and paclitaxel nanoparticles in anti-proliferation effect in normoxia and hypoxia: The basis of better selection of atherosclerosis treatment. 61
33024904 2021
20
miR‑212 promotes renal interstitial fibrosis by inhibiting hypoxia‑inducible factor 1‑α inhibitor. 61
33495813 2021
21
MicroRNA‑153 attenuates hypoxia‑induced excessive proliferation and migration of pulmonary arterial smooth muscle cells by targeting ROCK1 and NFATc3. 61
33495839 2021
22
The pathophysiological mechanism of ischemic stroke after hypobaric hypoxia simulation at high altitude. 61
33411214 2021
23
MicroRNA-135b-5p promotes endothelial cell proliferation and angiogenesis in diabetic retinopathy mice by inhibiting Von Hipp-el-Lindau and elevating hypoxia inducible factor α expression. 61
33032456 2021
24
Increased ratio of P[v-a]CO2 to C[a-v]O2 without global hypoxia: the case of metformin-induced lactic acidosis. 61
33202296 2021
25
Hypoxia and Hypoxia-Inducible Factor-1α Regulate Endoplasmic Reticulum Stress in Nucleus Pulposus Cells: Implications of Endoplasmic Reticulum Stress for Extracellular Matrix Secretion. 61
33307037 2021
26
Intratumoral Hypoxia and Mechanisms of Immune Evasion Mediated by Hypoxia-Inducible Factors. 61
33595388 2021
27
Hypoxia-induced therapy resistance: Available hypoxia-targeting strategies and current advances in head and neck cancer. 61
33465746 2021
28
The Expression and Role of Hypoxia-induced Factor-1α in Human Tenon's Capsule Fibroblasts under Hypoxia. 61
32767899 2021
29
Brain damage caused by neonatal hypoxia-ischemia and the effects of hypothermia in severe combined immunodeficient (SCID) mice. 61
33359474 2021
30
Up-regulating lncRNA OIP5-AS1 protects neuron injury against cerebral hypoxia-ischemia induced inflammation and oxidative stress in microglia/macrophage through activating CTRP3 via sponging miR-186-5p. 61
33516048 2021
31
Cutting Edge: Hypoxia-Induced Ubc9 Promoter Hypermethylation Regulates IL-17 Expression in Ulcerative Colitis. 61
33504619 2021
32
Phenotypic plasticity, genetic assimilation, and genetic compensation in hypoxia adaptation of high-altitude vertebrates. 61
33301891 2021
33
Obstructive sleep apnoea, intermittent hypoxia and heart failure with a preserved ejection fraction. 61
33414163 2021
34
Response to 'Obstructive sleep apnoea, intermittent hypoxia and heart failure with a preserved ejection fraction'. 61
33414164 2021
35
Zenglv Fumai Granule protects cardiomyocytes against hypoxia/reoxygenation-induced apoptosis via inhibiting TRIM28 expression. 61
33398366 2021
36
Hypoxia-induced inhibition of mTORC1 activity in the developing lung: a possible mechanism for the developmental programming of pulmonary hypertension. 61
33416457 2021
37
Mice with a specific deficiency of Pfkfb3 in myeloid cells are protected from hypoxia-induced pulmonary hypertension. 61
33300142 2021
38
Physiological resiliency in diving mammals: Insights on hypoxia protection using the Krogh principle to understand COVID-19 symptoms. 61
33227435 2021
39
The influence of summer hypoxia on sedimentary phosphorus biogeochemistry in a coastal scallop farming area, North Yellow Sea. 61
33250257 2021
40
Exposure to Nitrate Increases Susceptibility to Hypoxia in Fish. 61
33529124 2021
41
Hypoxia-reoxygenation stress modulates the hepatopancreas transcriptome of Chinese mitten crab Eriocheir sinensis. 61
33338508 2021
42
The effects of NO on the urea cycle pathway in short-term intermittent hypobaric hypoxia in rats. 61
33326865 2021
43
Prenatal hypoxia predisposes vascular functional and structural changes associated with oxidative stress damage and depressive behavior in adult offspring male rats. 61
33338483 2021
44
Occlusion of activity dependent synaptic plasticity by late hypoxic long term potentiation after neonatal intermittent hypoxia. 61
33358869 2021
45
Evodiamine inhibits vasculogenic mimicry in HCT116 cells by suppressing hypoxia-inducible factor 1-alpha-mediated angiogenesis. 61
33394687 2021
46
Activation of arginase II by asymmetric dimethylarginine and homocysteine in hypertensive rats induced by hypoxia: a new model of nitric oxide synthesis regulation in hypertensive processes? 61
33149269 2021
47
USP7, negatively regulated by miR-409-5p, aggravates hypoxia-induced cardiomyocyte injury. 61
33241864 2021
48
Sustained Hypoxia Reduces GABAergic Modulation on NTS Neurons Sending Projections to Ventral Medulla of Rats. 61
33421568 2021
49
Association of hypoxia and mitochondrial damage associated molecular patterns in the pathogenesis of vein graft failure: a pilot study. 61
32861831 2021
50
In vivo evaluation of percutaneous carbon dioxide treatment for improving intratumoral hypoxia using 18F-fluoromisonidazole PET-CT. 61
33574946 2021

Variations for Hypoxia

Expression for Hypoxia

Search GEO for disease gene expression data for Hypoxia.

Pathways for Hypoxia

Pathways related to Hypoxia according to GeneCards Suite gene sharing:

(show all 22)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
14.23 VHL VEGFA PSMA7 HIF3A HIF1AN HIF1A
2 12.88 VHL VEGFA MTOR HIF1A EPAS1 EP300
3
Show member pathways
12.66 VHL VEGFA MTOR HIF1A EPAS1 EP300
4
Show member pathways
12.45 VHL VEGFA PSMA7 MTOR HIF3A HIF1AN
5 12.32 MTOR HIF1AN HIF1A EPAS1 EGLN1 CA9
6 11.9 HIF1AN HIF1A EP300 EGLN1 CA9 ARNT
7
Show member pathways
11.89 VHL VEGFA HIF1A EPAS1 ARNT
8 11.85 VHL VEGFA MTOR HIF1A EP300 EGLN3
9
Show member pathways
11.75 VEGFA EP300 CITED2
10 11.74 VEGFA HIF1A EP300 EGLN3 EGLN1 CITED2
11
Show member pathways
11.69 VEGFA HIF1A EP300 ARNT
12 11.64 VHL VEGFA PSMA7 HIF1AN HIF1A EP300
13 11.62 TIGAR MTOR HIF1A
14 11.48 VEGFA HIF1AN HIF1A EGLN1 ARNT
15
Show member pathways
11.47 HIF1AN HIF1A EPAS1 EP300 EGLN3 CITED2
16 11.44 HIF1A EP300 ARNT
17 11.43 VEGFA EP300 ARNT
18 11.19 VHL VEGFA HIF1AN EPAS1 EP300 EGLN3
19 11.12 VEGFA HIF1A ARNT
20 11.01 VHL HIF3A HIF1AN HIF1A ARNT
21 10.96 VHL VEGFA EPAS1
22 10.67 VEGFA HIF1AN HIF1A

GO Terms for Hypoxia

Cellular components related to Hypoxia according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 cytosol GO:0005829 10.07 VHL TIGAR PSMA7 MTOR KMT2A HILPDA
2 cytoplasm GO:0005737 10.03 VHL VEGFA TIGAR PSMA7 MTOR HIF3A
3 nucleus GO:0005634 9.86 VHL TIGAR PSMA7 MTOR KMT2A HIF3A
4 transcription factor complex GO:0005667 9.62 HIF1A EPAS1 EP300 ARNT
5 nucleoplasm GO:0005654 9.47 VHL PSMA7 MTOR KMT2A HILPDA HIF3A

Biological processes related to Hypoxia according to GeneCards Suite gene sharing:

(show all 25)
# Name GO ID Score Top Affiliating Genes
1 positive regulation of transcription by RNA polymerase II GO:0045944 10.1 VEGFA KMT2A HIF1A EPAS1 EP300 CITED2
2 regulation of transcription, DNA-templated GO:0006355 10.1 VHL KMT2A HIF3A HIF1A EPAS1 EP300
3 positive regulation of transcription, DNA-templated GO:0045893 10.02 VHL KMT2A HIF1A EP300 CITED2 ARNT
4 negative regulation of apoptotic process GO:0043066 10 VHL VEGFA HYOU1 HIF1A CITED2
5 positive regulation of gene expression GO:0010628 9.97 VEGFA MTOR HIF1A EP300 CITED2
6 negative regulation of gene expression GO:0010629 9.92 VHL VEGFA HIF1A CITED2
7 angiogenesis GO:0001525 9.88 VEGFA HIF3A HIF1A EPAS1
8 post-translational protein modification GO:0043687 9.88 VHL PSMA7 HIF3A HIF1A EPAS1
9 cellular response to hypoxia GO:0071456 9.85 VEGFA TIGAR MTOR HYOU1 HILPDA HIF1A
10 lung development GO:0030324 9.78 VEGFA EPAS1 EP300
11 positive regulation of endothelial cell proliferation GO:0001938 9.73 VEGFA MTOR HIF1A ARNT
12 response to hypoxia GO:0001666 9.7 VEGFA HIF3A HIF1A EPAS1 EP300 EGLN3
13 outflow tract morphogenesis GO:0003151 9.69 VEGFA HIF1A CITED2
14 embryonic hemopoiesis GO:0035162 9.62 KMT2A HIF1A
15 embryonic placenta development GO:0001892 9.62 HIF1A EPAS1 CITED2 ARNT
16 positive regulation of vascular endothelial growth factor receptor signaling pathway GO:0030949 9.61 HIF1A ARNT
17 surfactant homeostasis GO:0043129 9.59 VEGFA EPAS1
18 regulation of transcription from RNA polymerase II promoter in response to oxidative stress GO:0043619 9.58 HIF1A EPAS1 ARNT
19 oxygen homeostasis GO:0032364 9.57 HIF1A EGLN1
20 peptidyl-proline hydroxylation to 4-hydroxy-L-proline GO:0018401 9.56 P4HTM EGLN3 EGLN2 EGLN1
21 regulation of protein neddylation GO:2000434 9.54 HIF1A EPAS1
22 negative regulation of transcription from RNA polymerase II promoter in response to hypoxia GO:0061428 9.54 VHL HIF1AN CITED2
23 positive regulation of transcription from RNA polymerase II promoter in response to hypoxia GO:0061419 9.52 VEGFA HIF1A
24 positive regulation of hormone biosynthetic process GO:0046886 9.46 HIF1A ARNT
25 regulation of transcription from RNA polymerase II promoter in response to hypoxia GO:0061418 9.44 VHL VEGFA PSMA7 HIF3A HIF1AN HIF1A

Molecular functions related to Hypoxia according to GeneCards Suite gene sharing:

(show all 14)
# Name GO ID Score Top Affiliating Genes
1 protein binding GO:0005515 10.5 VHL VEGFA TIGAR PSMA7 MTOR KMT2A
2 oxidoreductase activity GO:0016491 9.93 P4HTM HIF1AN EGLN3 EGLN2 EGLN1
3 transcription factor binding GO:0008134 9.89 VHL HIF1A EPAS1 EP300 ARNT
4 protein dimerization activity GO:0046983 9.81 HIF3A HIF1A EPAS1 ARNT
5 iron ion binding GO:0005506 9.76 P4HTM EGLN3 EGLN2 EGLN1
6 dioxygenase activity GO:0051213 9.72 P4HTM HIF1AN EGLN3 EGLN2 EGLN1
7 oxidoreductase activity, acting on paired donors, with incorporation or reduction of molecular oxygen GO:0016705 9.71 P4HTM EGLN3 EGLN2 EGLN1
8 histone acetyltransferase binding GO:0035035 9.61 HIF1A EPAS1 CITED2
9 ferrous iron binding GO:0008198 9.56 HIF1AN EGLN3 EGLN2 EGLN1
10 peptidyl-proline dioxygenase activity GO:0031543 9.54 EGLN3 EGLN2 EGLN1
11 oxygen sensor activity GO:0019826 9.48 HIF1AN EGLN2
12 peptidyl-proline 4-dioxygenase activity GO:0031545 9.33 EGLN3 EGLN2 EGLN1
13 L-ascorbic acid binding GO:0031418 9.26 P4HTM EGLN3 EGLN2 EGLN1
14 oxidoreductase activity, acting on paired donors, with incorporation or reduction of molecular oxygen, 2-oxoglutarate as one donor, and incorporation of one atom each of oxygen into both donors GO:0016706 9.02 P4HTM HIF1AN EGLN3 EGLN2 EGLN1

Sources for Hypoxia

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
20 GARD
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
53 NINDS
54 Novoseek
56 OMIM via Orphanet
57 OMIM® (Updated 05-Mar-2021)
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 TGDB
70 Tocris
71 UMLS
72 UMLS via Orphanet
Content
Loading form....